Register Login
Register to leave comments
  • News bot March 26, 2026, 9:17 p.m.

    📋 DERMATA THERAPEUTICS, INC. (DRMAW) - Financial Results

    Filing Date: 2026-03-26

    Accepted: 2026-03-26 17:16:14

    Event Type: Financial Results

    Event Details:

    DERMATA THERAPEUTICS, INC. (DRMAW) Reports the reporting period Financial Results DERMATA THERAPEUTICS, INC. (DRMAW) announced its financial results for the period ending the reporting period. Key Financial Highlights:
    • Revenue: $15
    • Net Income: Not disclosed
    • EPS: Not disclosed
    • Cash and equivalents: 7522
      • targeting consumers suffering from common forms of acne. This OTC acne treatment will incorporate an FDA approved OTC active ingredient along with the Company’s Bioneedle, to provide patients with a targeted treatment for their acne. The Clearing Treatment is expected to launch shortly after the Foundational Treatment. Year Ended 2025

    📊 Key Financial Metrics (Year-over-Year Comparison):

    Metric 2025 2024 Change ($) Change (%)
    Assets Prepaid Expenses Other Current Assets 342.00 372.00 $-30.00 -8.06%
    Liabilities Accounts Payable 461.00 808.00 $-347.00 -42.95%
    Liabilities Accrued Liabilities 1.18K 1.17K $15.00 +1.29%
    Operating Expenses Selling General Administrative 4.84K 4.31K $535.00 +12.42%
    Operating Expenses Loss From Operations 7.77K 12.51K $-4.74K -37.87%
    Operating Expenses Net Loss 7.56K 12.29K $-4.73K -38.48%
    Operating Expenses Net Loss Per Share 8.16 80.32 $-72.16 -89.84%
    Includes The Following Stockbased Compensation Expense Selling General Administrative 112.00 406.00 $-294.00 -72.41%

    💼 Business Developments:

    • Partnership: Not available
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: DERMATA THERAPEUTICS, INC.
    • Ticker Symbol: DRMAW

Search

News categories